Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Medical Oncology

Building Your Care Team and Preparing for Visits

At a Glance

A coordinated lung cancer team may include medical, surgical, radiation, pulmonary, pathology, nursing, and supportive-care specialists. Before visits, bring imaging and reports, prepare your medical history and questions, and consider a second opinion at an experienced center.

Building the right care team is one of the most proactive steps you can take after a lung cancer diagnosis. Because modern lung cancer treatment is highly complex, it requires a multidisciplinary team—a group of specialists from different fields who engage in shared decision-making with you to create a personalized plan [1][2].

Your Comprehensive Lung Cancer Team

A high-quality lung cancer program integrates several key specialists to address both the disease and your overall well-being [1][3]:

  • Medical Oncologist: Specializes in treating cancer with systemic therapies like chemotherapy, immunotherapy, and targeted therapies [4].
  • Thoracic Surgeon: A surgeon with specialized training in operating on the lungs and chest. Research shows that surgical volume is associated with better outcomes for complex thoracic procedures, though it does not guarantee an individual result [5][6].
  • Radiation Oncologist: A doctor who uses high-energy radiation to kill cancer cells or shrink tumors [1].
  • Pulmonologist / Interventional Pulmonologist: Helps with diagnosis, manages breathing symptoms, and performs procedures to open blocked airways [2][7].
  • Pathologist: Examines your tissue and performs genetic biomarker testing [1][8].
  • Palliative / Supportive Care Specialist: Focuses on relieving symptoms (pain, breathlessness, nausea) and improving quality of life concurrently with your cancer-directed treatment.
  • Nurse Navigator: A dedicated coordinator who acts as your primary point of contact, helping manage appointments and explaining your treatment plan [9].
  • Supportive Professionals: Social workers, oncology dietitians, and rehabilitation therapists who help with nutrition, financial hurdles, transportation, and physical recovery.

Vetting Your Care Team

When meeting a new team, you have the right to ask questions to ensure they have the expertise necessary to treat your specific cancer [5].

  1. Multidisciplinary Tumor Board: Ask if your case will be discussed at a tumor board—a meeting where specialists review your scans and pathology together to recommend a treatment strategy [10][11].
  2. Experience and Volume: Ask how many lung cancer cases the doctor and the hospital treat annually. Higher volume is generally a recognized indicator of quality care [5][12].
  3. Comprehensive Testing: Ensure the team utilizes comprehensive biomarker testing (NGS) to guide treatment decisions [8][10].

The Value of a Second Opinion

Lung cancer science is moving incredibly fast. Seeking a second opinion—especially at a high-volume center or an NCI-Designated Cancer Center—can be invaluable [13][14]. These centers often have access to specialized clinical trials and advanced diagnostic tools [15][16]. A second opinion can confirm your diagnosis, suggest alternative treatments, or provide peace of mind [17][18]. Note that hospital systems usually arrange the secure transfer of your physical tissue blocks and slides if needed.

Preparing for Your First Appointment

To make the most of your first visit, arrive prepared with your medical history [9].

  • Imaging Discs: Obtain the actual image files (in DICOM format) on a CD or USB drive for every CT, PET, or MRI scan you have had [18].
  • Pathology and Molecular Reports: Bring paper copies of your biopsy and biomarker results.
  • Medical History: A comprehensive list of all current medications, allergies, past surgeries, and your smoking or occupational exposure history [19][20].
  • A Support Person: Bring a friend or family member to take notes, as the amount of information shared can be overwhelming.

Common questions in this guide

Which specialists may be involved in my lung cancer care?
A lung cancer team may include a medical oncologist, thoracic surgeon, radiation oncologist, pulmonologist, pathologist, nurse navigator, and palliative or supportive-care specialist. Social workers, dietitians, and rehabilitation professionals may also help with practical needs and recovery.
What is a lung cancer tumor board, and why is it useful?
A tumor board is a meeting where specialists review your scans, tissue results, and other medical information together. Their combined review can help the team recommend a coordinated treatment plan tailored to your cancer.
Should I get a second opinion after a lung cancer diagnosis?
A second opinion can confirm the diagnosis, identify other treatment options, or provide reassurance. A high-volume lung cancer center or NCI-Designated Cancer Center may also offer specialized testing and access to clinical trials.
What should I bring to my first lung cancer appointment?
Bring copies of your pathology and molecular reports, imaging files from CT, PET, or MRI scans, and a complete list of medications, allergies, prior surgeries, and smoking or occupational exposures. A trusted friend or family member can take notes and help you remember information.
How can I evaluate a lung cancer treatment center?
Ask whether your case will be reviewed by a multidisciplinary thoracic tumor board, how many similar lung cancer cases the team treats each year, and whether comprehensive biomarker testing is available. These questions can help you understand the center’s experience and approach to coordinated care.
Can palliative care start while I am receiving cancer treatment?
Yes. Palliative or supportive care can be provided at the same time as cancer-directed treatment to help manage symptoms such as pain, breathlessness, and nausea while supporting quality of life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Will my case be presented at a multidisciplinary thoracic tumor board?
  2. 2.How many lung cancer cases like mine do you and this hospital treat each year?
  3. 3.Is there a nurse navigator or clinical coordinator who will be my main point of contact?
  4. 4.How do we integrate palliative and supportive care into my treatment plan starting now?
  5. 5.Is there an established process here for independent pathology review if I bring in materials from elsewhere?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.

    Salgia R

    Future oncology (London, England) 2015; (11(3)):489-500 doi:10.2217/fon.14.275.

    PMID: 25675128
  2. 2

    Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

    Villar Álvarez F, Muguruza Trueba I, Belda Sanchis J, et al.

    Archivos de bronconeumologia 2016; (52(7)):378-88.

    PMID: 27237592
  3. 3

    Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists.

    Glatzer M, Leskow P, Caparrotti F, et al.

    Translational lung cancer research 2021; (10(4)):1960-1968 doi:10.21037/tlcr-20-1210.

    PMID: 34012806
  4. 4

    Rare renal metastasis: Oligometastatic non-small cell lung cancer diagnosed with ultrasound guided renal biopsy.

    Neerhut T, McMaster T, Homewood D, et al.

    Radiology case reports 2026; (21(3)):1291-1296 doi:10.1016/j.radcr.2025.12.012.

    PMID: 41551102
  5. 5

    European Respiratory Society guideline on various aspects of quality in lung cancer care.

    Blum TG, Morgan RL, Durieux V, et al.

    The European respiratory journal 2023; (61(2)) doi:10.1183/13993003.03201-2021.

    PMID: 36396145
  6. 6

    Association between surgical quality and long-term survival in lung cancer.

    Lee JD, Zheng R, Okusanya OT, et al.

    Lung cancer (Amsterdam, Netherlands) 2024; (190()):107511 doi:10.1016/j.lungcan.2024.107511.

    PMID: 38417278
  7. 7

    Using a Dedicated Interventional Pulmonology Practice Decreases Wait Time Before Treatment Initiation for New Lung Cancer Diagnoses.

    Benn BS, Parikh M, Tsau PH, et al.

    Lung 2019; (197(2)):249-255 doi:10.1007/s00408-019-00207-6.

    PMID: 30783733
  8. 8

    Molecular testing in non-small cell lung cancer: A consensus recommendation.

    Lai GGY, Cheng XM, Ang YL, et al.

    Annals of the Academy of Medicine, Singapore 2023; (52(7)):364-373 doi:10.47102/annals-acadmedsg.2022473.

    PMID: 38904502
  9. 9

    'Care for Outcomes': systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer.

    Cramer-van der Welle CM, van Loenhout L, van den Borne BE, et al.

    BMJ open 2021; (11(1)):e043229 doi:10.1136/bmjopen-2020-043229.

    PMID: 33452199
  10. 10

    [Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version].

    Schütte W, Gütz S, Nehls W, et al.

    Pneumologie (Stuttgart, Germany) 2023; (77(10)):671-813 doi:10.1055/a-2029-0134.

    PMID: 37884003
  11. 11

    A review on the impact of lung cancer multidisciplinary care on patient outcomes.

    Heinke MY, Vinod SK

    Translational lung cancer research 2020; (9(4)):1639-1653 doi:10.21037/tlcr.2019.11.03.

    PMID: 32953538
  12. 12

    Peri- and postoperative management of stage I-III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?

    Numan RC, Berge MT, Burgers JA, et al.

    Lung cancer (Amsterdam, Netherlands) 2016; (101()):129-136 doi:10.1016/j.lungcan.2016.06.007.

    PMID: 27794401
  13. 13

    A National Survey of Palliative Care Team Compositions.

    Chen J, de la Rosa A, Lai D, et al.

    Journal of palliative care 2022; (37(2)):142-151 doi:10.1177/08258597211058963.

    PMID: 34939878
  14. 14

    Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation.

    Frosch ZAK, Illenberger N, Mitra N, et al.

    JAMA network open 2021; (4(7)):e2115675 doi:10.1001/jamanetworkopen.2021.15675.

    PMID: 34241630
  15. 15

    Variations in cancer centers' use of cytology for the diagnosis of small cell lung carcinoma in the National Cancer Data Base.

    Gansler T, Fedewa SA, Lin CC, et al.

    Cancer cytopathology 2016; (124(1)):44-52 doi:10.1002/cncy.21610.

    PMID: 26332638
  16. 16

    Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers.

    de Moor JS, Mollica M, Sampson A, et al.

    JNCI cancer spectrum 2021; (5(3)) doi:10.1093/jncics/pkab033.

    PMID: 34222790
  17. 17

    Improving coordination of lung cancer care at a tertiary healthcare center in Saudi Arabia.

    Alkhathlan A, Alfaiz R, Almusallam G, et al.

    Saudi medical journal 2022; (43(3)):313-316 doi:10.15537/smj.2022.43.3.20210750.

    PMID: 35256500
  18. 18

    Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.

    Dietel M, Bubendorf L, Dingemans AM, et al.

    Thorax 2016; (71(2)):177-84 doi:10.1136/thoraxjnl-2014-206677.

    PMID: 26530085
  19. 19

    Epidemiology of Lung Cancer.

    Schwartz AG, Cote ML

    Advances in experimental medicine and biology 2016; (893()):21-41 doi:10.1007/978-3-319-24223-1_2.

    PMID: 26667337
  20. 20

    Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology.

    Laguna JC, García-Pardo M, Alessi J, et al.

    Therapeutic advances in medical oncology 2024; (16()):17588359241231260 doi:10.1177/17588359241231260.

    PMID: 38455708

This page is for educational purposes and does not replace medical advice. Your lung cancer team can help you choose specialists, interpret your records, and decide whether a second opinion is appropriate.

Get notified when new evidence is published on lung cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.